WallStreetZen

NASDAQ: GILD
Gilead Sciences Inc Stock Ownership

Insider buying vs selling

Have Gilead Sciences Inc insiders been buying or selling?
Buy
Sell
NameRoleDateSharesPriceValue
Brett A. PletcherEVPCorp Affairs & Gen Counsel2021-03-111,486$63.36
$94.15kSell
Merdad ParseyChief Medical Officer2021-03-101,639$63.91
$104.75kSell
Johanna MercierChief Commercial Officer2021-03-101,435$63.91
$91.71kSell
Diane E. WilfongSVP Controller & CAO2021-03-10609$63.91
$38.92kSell
Andrew D. DickinsonChief Financial Officer2021-03-101,771$63.91
$113.18kSell
Brett A. PletcherEVPCorp Affairs & Gen Counsel2021-03-101,107$63.91
$70.75kSell
Daniel Patrick OdayChairman & CEO2021-03-105,123$63.91
$327.41kSell
Daniel Patrick OdayChairman & CEO2021-03-105,123$63.91
$327.41kSell
Daniel Patrick OdayChairman & CEO2021-03-0124,620$62.46
$1.54MSell
Andrew D. DickinsonChief Financial Officer2021-02-15364$56.86
$20.70kBuy

1 of 5

GILD insiders have sold more GILD shares than they have bought in the last year
Ownership

GILD Shareholders

What type of owners hold Gilead Sciences Inc stock?
Institutional
Insider
Retail
NameHoldSharesValueType
Capital Research Global Investors9.71%121,672,399$7.87BInstitution
Blackrock Inc8.87%111,183,334$7.19BInstitution
Vanguard Group Inc8.20%102,787,017$6.65BInstitution
State Street Corp4.40%55,206,559$3.57BInstitution
Capital International Investors3.71%46,548,996$3.01BInstitution
Capital World Investors3.07%38,534,588$2.49BInstitution
Geode Capital Management LLC1.60%20,078,920$1.30BInstitution
Dodge Cox1.36%17,107,888$1.11BInstitution
Northern Trust Corp1.22%15,243,829$985.67MInstitution
Bank Of New York Mellon Corp1.10%13,806,532$892.73MInstitution

1 of 3

Gilead Sciences Stock Ownership FAQ

Who owns Gilead Sciences?

Gilead Sciences (NASDAQ: GILD) is owned by 77.30% institutional shareholders, 1.02% Gilead Sciences insiders, and 21.68% retail investors. Capital Research Global Investors is the largest individual Gilead Sciences shareholder, owning 121.67M shares representing 9.71% of the company. Capital Research Global Investors's Gilead Sciences shares are currently valued at $7.90B.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.